Amanda Mocroft
Overview
Explore the profile of Amanda Mocroft including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
246
Citations
4891
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kraef C, Roen A, Podlekareva D, Bakowska E, Nemeth J, Knappik M, et al.
Eur Respir J
. 2025 Feb;
PMID: 39978858
Background: Tuberculosis remains the leading cause of death among people with HIV. The aim of this study was to describe the incidence of tuberculosis (TB), explore risk factors and to...
2.
Raben D, Jakobsen M, Trajanovska J, Kowalska J, Vassilenko A, Dragas S, et al.
PLoS One
. 2025 Jan;
20(1):e0316794.
PMID: 39879174
Many HIV clinics with poor IT-infrastructure are unable to report data on individuals in care with HIV, on antiretroviral treatment (ART) and virologically suppressed (VS), with the aim of monitoring...
3.
Pelchen-Matthews A, Mocroft A, Ryom L, Ross M, Sharma S, Coca S, et al.
Kidney Int
. 2024 Nov;
106(6):1196.
PMID: 39577998
No abstract available.
4.
Johansen I, Roen A, Kraef C, Martin-Iguacel R, Nemeth J, Fenner L, et al.
Int J Infect Dis
. 2024 Aug;
147:107199.
PMID: 39142437
Objectives: Tuberculosis (TB) risk after initiation of antiretroviral treatment (ART) is not well described in a European setting, with an average TB incidence of 25/10 in the background population. Methods:...
5.
Roen A, Peters L, Wandeler G, Van Der Valk M, Zangerle R, Gunthard H, et al.
Open Forum Infect Dis
. 2024 Jun;
11(6):ofae308.
PMID: 38919512
Background: While use of some older antiretroviral drugs (ARVs) is associated with chronic liver enzyme elevation (cLEE), the impact of newer ARVs remains unknown. Methods: People with HIV enrolled in...
6.
Pelchen-Matthews A, Mocroft A, Ryom L, Ross M, Sharma S, Coca S, et al.
Kidney Int
. 2024 May;
106(1):136-144.
PMID: 38697479
People with human immunodeficiency virus (HIV) are at risk for chronic kidney disease (CKD) due to HIV and antiretroviral therapy (ART) nephrotoxicity. Immediate ART initiation reduces mortality and is now...
7.
Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, et al.
Clin Infect Dis
. 2024 Apr;
79(5):1242-1257.
PMID: 38663013
Background: Mortality among people with human immunodeficiency virus (HIV) declined with the introduction of combination antiretroviral therapy. We investigated trends in mortality in people with HIV from 1999 through 2020....
8.
Byonanebye D, Polizzotto M, Maltez F, Rauch A, Grabmeier-Pfistershammer K, Wit F, et al.
Lancet HIV
. 2024 Apr;
11(5):e321-e332.
PMID: 38621392
Background: Integrase strand-transfer inhibitors (INSTIs) and tenofovir alafenamide have been associated with weight gain in several clinical trials and observational cohorts. However, whether weight gain associated with INSTIs and tenofovir...
9.
Chammartin F, Mocroft A, Egle A, Zangerle R, Smith C, Mussini C, et al.
Clin Infect Dis
. 2023 Dec;
78(4):995-1004.
PMID: 38092042
Background: Human immunodeficiency virus (HIV) infection leads to chronic immune activation/inflammation that can persist in virally suppressed persons on fully active antiretroviral therapy (ART) and increase risk of malignancies. The...
10.
Mocroft A, Pelchen-Matthews A, Hoy J, Llibre J, Neesgaard B, Jaschinski N, et al.
AIDS
. 2023 Dec;
38(4):497-508.
PMID: 38079588
Objectives: People with HIV and extensive antiretroviral exposure may have limited/exhausted treatment options (LExTO) due to resistance, comorbidities, or antiretroviral-related toxicity. Predictors of LExTO were investigated in the RESPOND cohort....